Release Date: July 5, 2007

Valid Through: July 4, 2008

Credits Available: Physicians - 0.5 AMA PRA Category 1 Credit(s)^TM



Fee: There is no fee for this activity

This CME activity is based on the following:

Updates in the Management of Chronic Myeloid Leukemia (CML): A Report from ASCO 2007 

Myelodysplastic Syndrome: An Update from ASCO 2007 

Author: Hagop Kantarjian, MD, Chairman, Leukemia Department, M.D. Anderson Cancer Center

Hagop M. Kantarjian, MD

Dr. Hagop M. Kantarjian joined The University of Texas M. D. Anderson Cancer Center in 1981 as a fellow in the Department of Developmental Therapeutics and joined the faculty in 1983.  He currently serves as professor of medicine and chairman of the Department of Leukemia, directs the world’s largest comprehensive leukemia program, and holds the Kelcie Margaret Kana Research Chair.

Dr. Kantarjian is actively involved in research in both acute and chronic forms of leukemia.  By any measure, he is considered one of the most productive international leaders in the leukemia field today.  Among his accomplishments, Dr. Kantarjian has demonstrated the effectiveness of chemotherapeutic and biologic agents for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL).  He developed the Hyper-CVAD regimen which is now a standard of care in ALL.  He also developed new therapies for refractory leukemia and defined key prognostic factors that have increased patient survival.  His research has also provided better insight into the biology of leukemia, thereby suggesting additional therapies.

Dr. Kantarjian has taken an active role in the medical community, participating in numerous editorial boards and medical societies and holding administrative positions.  He has authored or co-authored more than 850 medical publications and abstracts and serves on editorial boards for four scientific journals.  In 1997, he received the first Emil J Freireich Award for Outstanding Clinical Research at M. D. Anderson.  Dr. Kantarjian was named a Scholar of the Leukemia Society of America from 1989 to 1994 and a Special Fellow of the Leukemia Society of America from 1982 to 1983.

 

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss results of a trial evaluating a thrombomimetic agent for the management of thrombocytopenia in MDS patients.
• Discuss hypomethylating agents and impact on hematologic improvement.
• Explain the role of growth factors in MDS.
• Evaluate data presented at ASCO regarding prognostic factors for MDS patients.
• Describe clinical trial results for the management of imatinib-failures for patients with CML.
• Discuss new strategies for the treatment of newly diagnosed CML.
• Identify new tyrosine kinase inhibitors being evaluated in CML.
  

Disclaimer

Notwithstanding any language to the contrary, nothing contained herein constitutes, nor is intended to constitute, an offer, inducement, promise, or contract of any kind. The data contained herein are for informational purposes only and are not represented to be error free. Any links to non-Creative Educational Concepts, Inc. (CEC) information are provided as a courtesy. They are not intended to constitute, nor do they constitute, an endorsement of the linked materials by CEC .

Supporters

This activity is supported by an educational donation provided by Amgen and an unrestricted educational grant from Bristol-Myers Squibb Company.